-

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that Rob Barrow, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT.

“It is a privilege to participate in the J.P. Morgan Healthcare Conference as we continue to share the progress MindMed is making to forge a new era of psychiatry,” said Rob Barrow, Chief Executive Officer. “The conference provides a meaningful opportunity to engage with the investment community as we prepare for a defining year ahead with three anticipated Phase 3 topline readouts, advancing toward potential FDA submissions in two of the largest psychiatry markets, GAD and MDD.”

A live audio webcast will be available to investors and other interested parties and can be accessed here.

The audio webcast replay will be available 24 hours after the webcast and active on MindMed’s website for 30 days.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health.

MindMed trades on NASDAQ under the symbol MNMD.

Contacts

For further information, please contact:

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co

Media:
media@mindmed.co

Industry:

Mind Medicine (MindMed) Inc.

NASDAQ:MNMD
Release Versions
English

Contacts

For further information, please contact:

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co

Media:
media@mindmed.co

More News From Mind Medicine (MindMed) Inc.

Definium Therapeutics Appoints Roger Adsett to Board of Directors

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. “We are thrilled to welcome Roger to our Board of Directors,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful ma...

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 88,850 common shares of the Company (the "Options") wit...

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical LSD in Mental Health Care...
Back to Newsroom